NASDAQ launches new Health Care Index
29 July, 2005 by Ruth BeranThe NASDAQ stock market has launched a new Health Care Index (NASDAQ:IXHC), a market-value weighted index that contains NASDAQ listed companies classified as health, pharmaceutical or biotechnology.
Rockeby biomed raises $1 million
29 July, 2005 by Ruth BeranSingapore's Rockeby biomed (ASX:RBY) has raised just over AUD$1 million in a non-renounceable one-for-one share rights issue to shareholders, approximately $786,000 less than the AUD$1.78 million it hoped for.
ChemGenex receives two ARC linkage grants
28 July, 2005 by Ruth BeranMelbourne and California-based ChemGenex Pharmaceuticals (ASX:CXS) has been awarded two linkage project grants worth AUD$525,000 in cash from the Australian Research Council (ARC) over the next three years.
EQiTX increases equity in ZingoTX
28 July, 2005 by Ruth BeranMelbourne-based biotech managed investment group EQiTX (ASX:EQX) has increased its ownership in pain management company ZingoTX to 54 per cent with an equity instalment of AUD$300,000, bringing its total investment in ZingoTX to $1.9 million.
EvoGenix raises $9 million in oversubscribed IPO
28 July, 2005 by Ruth BeranAntibody therapeutic developer EvoGenix closed its initial public offer (IPO) today oversubscribed, raising AUD$9 million through the issue of 36 million shares at $0.25.
New Chemeq CEO promises 'fresh eyes'
27 July, 2005 by Ruth BeranDavid Williams, the CEO designate of Perth-based antimicrobial specialist Chemeq (ASX:CMQ), begins his new role on August 1 and is excited about running the company.
Biota files claim of up to $430m against GSK
27 July, 2005 by Ruth BeranMelbourne-based biopharma Biota Holdings (ASX:BTA) today took the next step in its lawsuit against GlaxoSmithKline (GSK), filing particulars of loss and damage with the Victorian Supreme Court estimated to be in the range of AUD$308 million to $430 million.
Amrad lands US asthma patent
26 July, 2005 by Graeme O'NeillThe US Patent Office has granted Melbourne biopharma Amrad (ASX:AML) a patent on therapeutic antibodies that recognise for a sub-unit of the interleukin-13 (IL-13) receptor implicated in asthma.
UQ spin-off secures $3.25m for pain therapy
26 July, 2005 by Ruth BeranSpinifex Pharmaceuticals, a drug development company spun out of the University of Queensland, has received a AUD$3.25 million investment commitment to develop therapeutics for the treatment of neuropathic pain.
Chemeq names new CEO
26 July, 2005 by Ruth BeranAntimicrobial specialist Chemeq (ASX:CMQ) has named David Williams its new CEO and director, commencing August 1. Williams was formerly CEO of Epic Energy, a gas transmission company.
First C3 CellSpray XP patient treated
26 July, 2005 by Ruth BeranThe first patient has been treated with Clinical Cell Culture's (C3, ASX:CCE) CellSpray XP at Dortmund Hospital in Germany.
Avexa starts phase IIb trial of HIV drug
25 July, 2005 by Ruth BeranMelbourne-based biotech Avexa (ASX:AVX) has started the phase IIb trial of AVX754, the HIV compound it in-licensed from UK company Shire Pharmaceuticals in January.
Proteome Systems wins technology innovation award
21 July, 2005 by Graeme O'NeillProteome Systems has won a prestigious 2005 Frost and Sullivan Technology Innovation Award for its ingenious Chemical Inkjet Printer (ChIP).
In brief: Pharmaxis, Cochlear, OBJ, Cryptome Pharmaceuticals
21 July, 2005 by Staff WritersOn the back of yesterday's announcement, Pharmaxis (ASX:PXC) has been granted approval from Health Canada to conduct a clinical trial of Bronchitol in patients with cystic fibrosis.
Continence Control Systems starts first human implant recruitment
21 July, 2005 by Ruth BeranBioTech Capital (ASX:BTC) investee company Continence Control Systems International (CCS) has commenced patient recruitment for its severe urinary incontinence treatment, following completion of pre-clinical studies and human ethics approval for human implants.
